DexCom, Inc. (DXCM) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A session reveal positive sentiment. DexCom shows strong financial performance and optimistic guidance with revenue growth projected at 11%-13%. There are promising developments in product launches and expansion of Medicare coverage, particularly for the type 2 non-insulin population. Record new patient starts and international growth further support positive outlook. Although there is some uncertainty about the exact timing of CMS coverage, the overall tone is optimistic. The strategic focus on capital allocation and potential share buybacks also contributes positively to the sentiment.
Key Financial Performance
Revenue Worldwide revenue was $1.19 billion for Q1 2026, up 15% year-over-year from $1.04 billion in Q1 2025. Organic revenue growth was 12%. The increase was driven by strong demand for DexCom CGM globally, broader access, new product launches, and continued active base growth.
U.S. Revenue U.S. revenue totaled $832 million for Q1 2026, up 11% year-over-year from $751 million in Q1 2025. Growth was attributed to growing awareness of broader type 2 coverage and the launch of the G7 15 Day product.
International Revenue International revenue grew 26% to $360 million in Q1 2026. Organic international revenue growth was 17%. Growth was widespread, with significant increases in markets like France and Canada where access was recently expanded.
Gross Profit Gross profit was $757.4 million or 63.5% of revenue in Q1 2026, up from 57.5% of revenue in Q1 2025. The improvement was due to manufacturing efficiencies, normalized freight costs, improved global inventory levels, and benefits from the G7 15 Day product.
Operating Expenses Operating expenses were $493.0 million in Q1 2026, up from $453.1 million in Q1 2025. The increase reflects ongoing investments in operations and support teams.
Operating Income Operating income was $264.4 million or 22.2% of revenue in Q1 2026, up from $143.1 million or 13.8% of revenue in Q1 2025. This reflects strong operational execution and cost discipline.
Adjusted EBITDA Adjusted EBITDA was $364.5 million or 30.6% of revenue in Q1 2026, up from $230.4 million or 22.2% of revenue in Q1 2025. The increase was driven by improved operational performance and cost management.
Net Income Net income was $216.3 million or $0.56 per share in Q1 2026, representing 75% growth year-over-year. This reflects strong revenue growth and operational improvements.
Cash and Cash Equivalents Cash and cash equivalents were approximately $2.4 billion at the end of Q1 2026, up over $400 million from year-end 2025. This increase was driven by significant free cash flow performance in the quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
DexCom G7 15 Day system: Expanded launch across all channels in the U.S. with positive feedback from customers and physicians. Features include longer wear time and a new sensor algorithm for improved accuracy.
New patch technology: Received FDA clearance and expected to improve sensor survivability and wear experience. To be introduced in the coming weeks.
Stelo redesign: Complete redesign to offer a more consumer-friendly experience, AI-driven personalized insights, and enhanced food logging capabilities.
DexCom Smart Basal feature: Personalized dosing module for basal insulin management, aiming to improve insulin titration and outcomes.
Type 2 diabetes market expansion: Achieved significant share gains, especially among non-insulin users. Expanded coverage to over 6 million non-insulin lives, with plans to reach 7 million by year-end.
International market growth: Strong growth in markets like France and Canada due to recent reimbursement wins. Plans for international launch of Stelo and a new CGM system in 2026.
Revenue growth: Reported 15% year-over-year revenue growth, reaching $1.19 billion in Q1 2026.
Gross margin improvement: Gross profit margin increased to 63.5% from 57.5% in Q1 2025, driven by manufacturing efficiencies and normalized freight costs.
Cash flow generation: Closed Q1 with $2.4 billion in cash and cash equivalents, reflecting strong free cash flow performance.
CMS coverage for type 2 non-insulin population: Positioned as a key goal, with ongoing efforts to secure broader Medicare coverage.
Focus on customer experience: Prioritized setting the standard for customer experience through product innovation and personalization.
International market share expansion: Continued focus on tailoring products to specific markets and reimbursement systems to drive growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Gross Margin Guidance: The company has left gross margin guidance unchanged due to uncertainties in the geopolitical environment, including fuel prices and shipping routes, which could impact costs.
CMS Coverage for Type 2 Non-Insulin Population: The company views CMS coverage for the type 2 non-insulin population as a critical driver for growth, but acknowledges that this decision is pending and could delay broader market access.
International Market Expansion: While international markets are growing, the company faces challenges in tailoring products to different reimbursement systems and achieving broader access in some regions.
Supply Chain and Manufacturing: Although manufacturing efficiencies and normalized freight costs have improved, the company remains cautious about potential disruptions in the supply chain and geopolitical risks.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: Reaffirmed revenue guidance of $5.16 billion to $5.25 billion for 2026, representing growth of 11% to 13%.
Margin Projections: Reiterated full-year non-GAAP gross profit margin guidance of 63% to 64%. Increased non-GAAP operating profit margin guidance to 23% to 23.5% and adjusted EBITDA margin guidance to 31% to 31.5%.
Product Launches and Market Expansion: Plans to launch a new CGM system internationally in 2026 to extend market reach. Also, the international launch of Stelo is planned for 2026.
Type 2 Diabetes Coverage Expansion: Prime Therapeutics will begin covering DexCom CGM for all people with diabetes by summer 2026, aiming for commercial coverage of over 7 million type 2 non-insulin lives by year-end. CMS coverage for type 2 non-insulin population is expected to grow, with a randomized controlled trial readout planned for ADA's 2026 Scientific Sessions.
Product Updates: Expanded launch of DexCom G7 15 Day system in the U.S. with positive feedback. New patch technology with upgraded adhesive expected to reach the market in the coming weeks. Software updates, including a redesign of Stelo and AI-driven personalized insights, are planned.
International Growth Strategy: Focus on driving growth in international markets through broader access and new product launches, with strong growth expected in regions like France and Canada.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How is the U.S. market for CGM devices performing, and what is the company's perspective on growth opportunities?
A:The U.S. market for CGM devices is in a period of slower growth, with about 30% penetration into covered lives. This means only 1 in 3 people with coverage for CGM are using it. The company sees significant opportunities for growth, particularly with a new PBM covering CGM by the end of the year, adding 1 million lives to the non-insulin-using population. The company is targeting record numbers of new patients and believes there is a solid rate of growth ahead.
Q:What impact does the 15 Day product have on new patient starts and margins?
A:The 15 Day product is driving momentum with improved reliability, a new algorithm, and extended wear, which patients value. Nearly 50% of the base is expected to convert to the 15 Day product by year-end. On margins, there is a 50 to 100 basis point risk due to oil prices affecting fuels and resins, but the underlying business performance is strong, and the company is managing these risks effectively.
Q:What is the status of the randomized controlled trial (RCT) for the type 2 non-insulin population, and how does it impact growth?
A:The RCT results will be presented at ADA, with expectations of significant improvements in glucose outcomes and A1c reduction. The company anticipates this will unlock durable growth opportunities in the U.S. CGM market, particularly with continued commercial and Medicare coverage expansion.
Q:Did the company achieve record new patient starts this quarter?
A:Globally, the company achieved a record number of new patient starts this quarter. In the U.S., it was close to a record and showed sequential improvement from Q4. The company is optimistic about continued growth driven by coverage unlocks and product launches.
Q:What is the timeline and likelihood of CMS coverage for the type 2 non-insulin population?
A:CMS coverage for the type 2 non-insulin population is expected, though the exact timing is uncertain. The company believes the benefits of CGM for this category are clear and anticipates coverage will provide durable growth opportunities.
Q:What progress is being made on coverage unlocks outside the U.S.?
A:The company is making progress in unlocking basal coverage in international markets, with ongoing discussions and evidence generation. There were no one-time factors affecting the 17% OUS constant currency organic growth rate this quarter.
Q:How sustainable are the share gains in the type 2 population, and what factors contribute to this momentum?
A:The share gains in the type 2 population are driven by the 15 Day product, improved customer satisfaction scores, and the company's extensive coverage and low co-pays. The company is focused on continuing to take share and improving the customer experience.
Q:What trends are being observed in retention, and how does it impact growth?
A:Retention has been consistent within a band, and the company is targeting improvements through enhanced product and service experiences. Improved NPS scores indicate progress, which bodes well for future growth.
Q:What is the expected revenue growth rate for the remainder of the year, and are there any factors to consider?
A:The company expects 11% to 13% organic growth for the year, evenly split between U.S. and OUS. U.S. comps are more difficult in the first half and easier in the second half, while OUS comps are the opposite. The guidance includes nominal wins and assumes consistent performance.
Q:What is the status of the Smart Basal launch?
A:The Smart Basal system is in a pilot launch phase, focusing on fitting into clinical workflows. The company plans to broaden the launch throughout the year once all workflow issues are addressed.
Q:What are the company's expectations for CMS coverage and its impact on the type 2 non-insulin market?
A:CMS coverage is expected to significantly expand the market, with potential stipulations like requiring patients to be on diabetes medications. The company believes this will not limit the opportunity and expects it to drive durable growth.
Q:What is the progress and strategy for the Stelo product?
A:The Stelo product is tracking well and undergoing a redesign to improve user experience and insights. The international launch will start in select EMEA and APAC countries, with plans to expand further.
Q:What are the company's plans for capital allocation and use of cash?
A:The company is exploring opportunities for tuck-in M&A, share buybacks, and other strategic investments. More details will be provided at the upcoming Investor Day.
Q:What is the expected impact of the type 2 non-insulin market on financials and lifetime patient value?
A:The type 2 non-insulin market is expected to contribute significantly to growth, with lifetime patient value varying based on utilization. The company is focused on retention and utilization to maximize active base growth.
Q:What are the expectations for the RCT results and their significance?
A:The RCT is expected to show statistically significant A1c reductions, meeting reimbursement thresholds. The results will be presented at ADA and are anticipated to validate the benefits of CGM for the type 2 non-insulin population.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer on the exact timing of CMS coverage for the type 2 non-insulin population, stating it is a matter of time but not specifying when it will occur. Additionally, they did not provide detailed revenue growth expectations for specific quarters, instead reiterating annual guidance.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADA session
ATTD readout
Account web
Basal feature
CGM PBMs
CGM health
CGM manufacturing
CGM people
CGM reduction
Canada progress
DIaMonD MOBILE
Day improvement
Day income
Day market
Day priority
Day topic
Day uptake
DexCom CGM
DexCom Day
DexCom Smart
Dexcom
France Canada
Instructions
Investor Day
Jereme
Sean
demonstration
detail
diabetes care
diabetes insulin
ecosystem
field
health outcome
launch Day
life
market reimbursement
momentum spectrum
people diabetes
people type
product launch
product portfolio
reach
reimbursement win
response
software update
spectrum diabetes
DXCM Transcript
DexCom, Inc. (DXCM) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call summary and Q&A session reveal positive sentiment. DexCom shows strong financial performance and optimistic guidance with revenue growth projected at 11%-13%. There are promising developments in product launches and expansion of Medicare coverage, particularly for the type 2 non-insulin population. Record new patient starts and international growth further support positive outlook. Although there is some uncertainty about the exact timing of CMS coverage, the overall tone is optimistic. The strategic focus on capital allocation and potential share buybacks also contributes positively to the sentiment.
DexCom, Inc. (DXCM) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Neutral3-2
DexCom, Inc. (DXCM) Q4 2025 Earnings Call Transcript
Positive2-12
DexCom's earnings call indicates positive sentiment with raised revenue guidance, product launches, and international expansion plans. Despite lowered gross profit margin guidance, the company plans to offset this through operating expense leverage. The Q&A section reveals strong engagement in the basal segment, positive early results for the G7 product, and expanding coverage for type 2 diabetes users. While some uncertainties remain, such as CMS coverage timelines, the overall outlook with new product launches and international expansion is optimistic, suggesting a positive stock price reaction.
Novo Nordisk A/S (NOVO:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
DXCM Slides
DXCM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
